Johann S de Bono
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
Hoyle A, Aebersold D, Jones R, Matheson D, Millman R, Mason M, Ritchie A, Russell M, Douis H, Parmar M, Sydes M, Clarke N, Gillessen Sommer S, Ingleby F, Ali A, James N, Cook A, Parker C, de Bono J, Attard G, Chowdhury S, Cross W, Dearnaley D, Brawley C, Gilson C, STAMPEDE Investigators. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur Urol 2019; 76:719-728.
23.08.2019Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
23.08.2019Eur Urol 2019; 76:719-728
Hoyle Alex P, Aebersold Daniel M, Jones Rob J, Matheson David, Millman Robin, Mason Malcolm D, Ritchie Alastair W S, Russell Martin, Douis Hassan, Parmar Mahesh K B, Sydes Matthew R, Clarke Noel W, Gillessen Sommer Silke, Ingleby Fiona, Ali Adnan, James Nicholas D, Cook Adrian, Parker Christopher C, de Bono Johann S, Attard Gerhardt, Chowdhury Simon, Cross William R, Dearnaley David P, Brawley Christopher D, Gilson Clare, STAMPEDE Investigators
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Rescigno P, Romero-Laorden N, Castro E, Saez M, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S, Sternberg C, De Giorgi U, Olmos D, Morley C, Pezaro C, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, de Bono J. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. Eur Urol Oncol 2019
12.07.2019Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
12.07.2019Eur Urol Oncol 2019
Rescigno Pasquale, Romero-Laorden Nuria, Castro Elena, Saez Maria I, Mehra Niven, Smeenk Stella, Sideris Spyridon, Gil Thyerry, Banks Patricia, Sandhu Shaneen K, Sternberg Cora N, De Giorgi Ugo, Olmos David, Morley Courtney, Pezaro Carmel J, Dolling David, Conteduca Vincenza, Rediti Mattia, Bianchini Diletta, Lolli Cristian, Ong Michael, Li Haoran, Omlin Aurelius, Schmid Sabine, Caffo Orazio, Zivi Andrea, de Bono Johann S
Managing Nonmetastatic Castration-resistant Prostate Cancer
Mateo J, Tomlins S, Tombal B, Sweeney C, Smith M, Shore N, Oyen W, Pérez-López R, Heidenreich A, Gillessen Sommer S, Fizazi K, de Bono J. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2018
14.08.2018Managing Nonmetastatic Castration-resistant Prostate Cancer
14.08.2018Eur Urol 2018
Mateo Joaquin, Tomlins Scott A, Tombal Bertrand, Sweeney Christopher, Smith Matthew, Shore Neal, Oyen Wim J G, Pérez-López Raquel, Heidenreich Axel, Gillessen Sommer Silke, Fizazi Karim, de Bono Johann S
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
Sumanasuriya S, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein N, Terstappen L, Waugh D, Lorente D, Lolkema M, Omlin A, Armstrong A, Attard G, Chi K, Bevan C, Shibakawa A, IJzerman M, De Laere B, de Bono J. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. Eur Urol Oncol 2018; 1:151-159.
15.05.2018Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
15.05.2018Eur Urol Oncol 2018; 1:151-159
Sumanasuriya Semini, Luo Jun, Mehra Niven, Olmos David, Scher Howard, Soule Howard, Stoecklein Nikolas H, Terstappen Leon W M M, Waugh David, Lorente David, Lolkema Martijn, Omlin Aurelius, Armstrong Andrew, Attard Gerhardt, Chi Kim N, Bevan Charlotte L, Shibakawa Aki, IJzerman Maarten J, De Laere Bram, de Bono Johann S
Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.002
Gillessen Sommer S, de Bono J, Sartor O, Omlin A. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.002. Eur Urol 2017
28.08.2017Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.002
28.08.2017Eur Urol 2017
Gillessen Sommer Silke, de Bono Johann S, Sartor Oliver, Omlin Aurelius
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
STAMPEDE Investigators, McPhail N, McKinna F, Malik Z, Lester J, Hoskin P, Hingorani M, Gray E, Gale J, Ferguson C, Chakraborti P, Money-Kyrle J, O'Sullivan J, Sydes M, Parmar M, Zarkar A, Wylie J, Wagstaff J, Thomas C, Srihari N, Robinson A, Protheroe A, Parikh O, Brock S, Bowen J, Matheson D, Jones R, Gilson C, Amos C, Ritchie A, Dearnaley D, Mason M, Clarke N, Spears M, de Bono J, Millman R, Attard G, Birtle A, Aung S, Adab F, Brawley C, Berthold D, Russell J, Parker C, Gillessen Sommer S, Cross W, Chowdhury S, James N. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338-351.
03.06.2017Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
03.06.2017N Engl J Med 2017; 377:338-351
STAMPEDE Investigators, McPhail Neil, McKinna Fiona, Malik Zafar I, Lester Jason F, Hoskin Peter J, Hingorani Mohan, Gray Emma, Gale Joanna, Ferguson Catherine, Chakraborti Prabir, Money-Kyrle Julian, O'Sullivan Joe, Sydes Matthew R, Parmar Mahesh K B, Zarkar Anjali, Wylie James, Wagstaff John, Thomas Carys, Srihari Narayanan N, Robinson Angus, Protheroe Andrew, Parikh Omi, Brock Susannah, Bowen Jo, Matheson David, Jones Rob J, Gilson Clare, Amos Claire L, Ritchie Alastair W S, Dearnaley David P, Mason Malcolm D, Clarke Noel W, Spears Melissa R, de Bono Johann S, Millman Robin, Attard Gerhardt, Birtle Alison J, Aung San, Adab Fawzi, Brawley Chris, Berthold Dominik R, Russell J Martin, Parker Christopher C, Gillessen Sommer Silke, Cross William R, Chowdhury Simon, James Nicholas D
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial
James N, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar M, Sydes M, Engeler D, Birtle A, Spears M, Clarke N, Dearnaley D, Mason M, Parker C, Ritchie A, Russell J, Schiavone F, Attard G, de Bono J. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncol 2016; 2:348-57.
01.03.2016Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial
01.03.2016JAMA Oncol 2016; 2:348-57
James Nicholas D, Elliott Tony, Matheson David, O'Sullivan Joe, Pudney Delia, Srihari Narayanan, Wallace Jan, Barber Jim, Syndikus Isabel, Parmar Mahesh K B, Sydes Matthew R, Engeler Daniel, Birtle Alison, Spears Melissa R, Clarke Noel W, Dearnaley David P, Mason Malcolm D, Parker Christopher C, Ritchie Alastair W S, Russell J Martin, Schiavone Francesca, Attard Gerhardt, de Bono Johann S
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer
Pérez-López R, Koh D, de Bono J, Leach M, Zivi A, Omlin A, Bianchini D, Mateo J, Collins D, Blackledge M, Lorente D, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology 2016; 280:151-60.
25.01.2016Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer
25.01.2016Radiology 2016; 280:151-60
Pérez-López Raquel, Koh Dow-Mu, de Bono Johann S, Leach Martin O, Zivi Andrea, Omlin Aurelius, Bianchini Diletta, Mateo Joaquin, Collins David J, Blackledge Matthew D, Lorente David, Tunariu Nina
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel
Omlin A, Sartor O, Rothermundt C, Cathomas R, de Bono J, Shen L, Su Z, Gillessen Sommer S. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer 2015
30.01.2015Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel
30.01.2015Clin Genitourin Cancer 2015
Omlin Aurelius, Sartor Oliver, Rothermundt Christian, Cathomas Richard, de Bono Johann S, Shen Liji, Su Zhen, Gillessen Sommer Silke
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014; 120:3346-52.
03.07.2014Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
03.07.2014Cancer 2014; 120:3346-52
Templeton Arnoud, Tannock Ian F, de Bono Johann S, Attard Gerhardt, Vera-Badillo Francisco E, Leibowitz-Amit Raya, McNamara Mairead G, Omlin Aurelius, Pezaro Carmel, Amir Eitan
Circulating tumor cells: a multifunctional biomarker
Yap T, Lorente D, Omlin A, Olmos D, de Bono J. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014; 20:2553-68.
15.05.2014Circulating tumor cells: a multifunctional biomarker
15.05.2014Clin Cancer Res 2014; 20:2553-68
Yap Timothy A, Lorente David, Omlin Aurelius, Olmos David, de Bono Johann S
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
Loriot Y, Ouatas T, Holtkamp G, Baron B, Heeringa M, Baskin-Bey E, James N, Omlin A, Molife R, Van den Brande J, Jones R, Fizazi K, de Bono J. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs 2014; 32:995-1004.
27.04.2014Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
27.04.2014Invest New Drugs 2014; 32:995-1004
Loriot Yohann, Ouatas Taoufik, Holtkamp Gertjan M, Baron Benoit, Heeringa Marten, Baskin-Bey Edwina, James Nicholas D, Omlin Aurelius, Molife Rhoda L, Van den Brande Jan, Jones Robert J, Fizazi Karim, de Bono Johann S
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
de Bono J, Scranton J, Wang T, Hudes G, Gillessen Sommer S, Fong P, Sandhu S, Aparicio L, Saad F, Petrylak D, Pandha H, Piulats J, Pollak M. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res 2014; 20:1925-34.
17.02.2014Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
17.02.2014Clin Cancer Res 2014; 20:1925-34
de Bono Johann S, Scranton Judith, Wang Tao, Hudes Gary R, Gillessen Sommer Silke, Fong Peter, Sandhu Shahneen K, Aparicio Luis Miguel A, Saad Fred, Petrylak Daniel P, Pandha Hardev S, Piulats Josep M, Pollak Michael N
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Molife L, Pelling K, Temple G, Heath C, Wheatley D, Oommen N, Thompson E, Jenkins P, Hickish T, Pedley I, O'Sullivan J, Olmos D, Fong P, Lumsden G, Bloomfield D, Karavasilis V, Jones R, Omlin A, de Bono J. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol 2014; 10:219-31.
01.02.2014Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
01.02.2014Future Oncol 2014; 10:219-31
Molife L Rhoda, Pelling Katy, Temple Graham, Heath Catherine, Wheatley Duncan, Oommen Nikhil, Thompson Emilda, Jenkins Peter, Hickish Tamas, Pedley Ian, O'Sullivan Joe M, Olmos David, Fong Peter C, Lumsden Graeme, Bloomfield David, Karavasilis Vasilios, Jones Rob J, Omlin Aurelius, de Bono Johann S
Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
Lorente D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Bianchini D, de Bono J. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. Eur J Cancer 2014; 50:1042-3.
13.01.2014Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
13.01.2014Eur J Cancer 2014; 50:1042-3
Lorente David, Chowdhury Simon, Attard Gerhardt, Zivi Andrea, Ferraldeschi Roberta, Pezaro Carmel, Omlin Aurelius, Rodriguez-Vida Alejo, Bianchini Diletta, de Bono Johann S
Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
Pezaro C, de Bono J, Parker C, Dearnaley D, Bianchini D, Ferraldeschi R, Lorente D, Altavilla A, Omlin A, Attard G. Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. Eur Urol 2013
17.12.2013Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
17.12.2013Eur Urol 2013
Pezaro Carmel J, de Bono Johann S, Parker Christopher, Dearnaley David, Bianchini Diletta, Ferraldeschi Roberta, Lorente David, Altavilla Amelia, Omlin Aurelius, Attard Gerhardt
Visceral Disease in Castration-resistant Prostate Cancer
Pezaro C, de Bono J, Tunariu N, Crespo M, Altavilla A, Riisnaes R, Mukherji D, Bianchini D, Ferraldeschi R, Nava Rodrigues D, Lorente D, Omlin A, Attard G. Visceral Disease in Castration-resistant Prostate Cancer. Eur Urol 2013; 65:270-3.
22.11.2013Visceral Disease in Castration-resistant Prostate Cancer
22.11.2013Eur Urol 2013; 65:270-3
Pezaro Carmel J, de Bono Johann S, Tunariu Nina, Crespo Mateus, Altavilla Amelia, Riisnaes Ruth, Mukherji Deborah, Bianchini Diletta, Ferraldeschi Roberta, Nava Rodrigues Daniel, Lorente David, Omlin Aurelius, Attard Gerhardt
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Sandhu S, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter C, Iannone R, Kaye S, de Bono J, Thway K, Kreischer N, Schelman W, Wilding G, Moreno V, Baird R, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Wenham R. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14:882-92.
28.06.2013The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
28.06.2013Lancet Oncol 2013; 14:882-92
Sandhu Shahneen K, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Thway Khin, Kreischer Nathan, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Wenham Robert M
Development of therapeutic combinations targeting major cancer signaling pathways
Yap T, Omlin A, de Bono J. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013; 31:1592-605.
18.03.2013Development of therapeutic combinations targeting major cancer signaling pathways
18.03.2013J Clin Oncol 2013; 31:1592-605
Yap Timothy A, Omlin Aurelius, de Bono Johann S
Therapeutic options for advanced prostate cancer: 2011 update
Omlin A, de Bono J. Therapeutic options for advanced prostate cancer: 2011 update. Curr Urol Rep 2012; 13:170-8.
01.04.2012Therapeutic options for advanced prostate cancer: 2011 update
01.04.2012Curr Urol Rep 2012; 13:170-8
Omlin Aurelius, de Bono Johann S